Dual CEA/CD44 targeting to colorectal cancer cells using nanobody-conjugated hyaluronic acid-modified mesoporous silica nanoparticles with pH- and redox-sensitivity
Xiying Fan, Tingting Wang, Min Ho Han, Yi Gu, Guochuan Sun, Xinying Peng, Qinghui Shou, Haipeng Song, Wenshuai Liu, Rui Nian
Abstract
Mesoporous silica nanoparticles (MSNs) loaded with doxorubicin and then modified with hyaluronic acid (HA) and nanobody (DOX@MSNs-HA-11C12) is a pH- and redox-responsive drug delivery system, resulting in over 90% of LoVo cell apoptosis within 48 h.
Topics & Concepts
Hyaluronic acidMesoporous silicaDoxorubicinChemistryRedoxNanoparticleCD44Conjugated systemDrug deliveryMesoporous materialBiophysicsCancer researchCellNanotechnologyMaterials scienceChemotherapyBiochemistryMedicineInorganic chemistryOrganic chemistryCatalysisInternal medicinePolymerAnatomyBiologyGlycosylation and Glycoproteins ResearchNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranostics